<DOC>
	<DOC>NCT01882712</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe chronic persistent vascular facial erythema</brief_summary>
	<brief_title>Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema</brief_title>
	<detailed_description />
	<mesh_term>Erythema</mesh_term>
	<criteria>Male or female, who is at least 18 years of age or older at screening visit. Presence of chronic persistent vascular facial erythema for ≥ 3 months by history. A Clinician's Erythema Assessment (CEA) score of ≥3 at Screening and at Predose (T0) on Baseline/Day 1. A Patient Self Assessment (PSA) score of ≥3 at Screening and at Predose (T0) on Baseline/Day 1. More than 2 facial inflammatory lesions (papules, pustules, and nodules). Presence of areas of significant scaling or crusting on the face. Presence of psoriatic lesions on the face. Presence of any other dermatological condition of the face that, in the opinion of the Investigator, may significantly interfere with the interpretation of the clinical trial results.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>